Loading asset research
Q3 2026 earnings · Nov 3
Biomea Fusion Inc. Common Stock
BMEANasdaq · USD · StocksQuote as of · Exchange session not verified$1.49
+3.47%
Today
BMEA
Loading 1D prices…
Market cap
$99.7M
Volume
2.2M
52w high
$2.9952w low
$0.872Company profile
Biomea Fusion Inc. Common Stock
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
SAN CARLOS, CA, United States
Employees
37
Fiscal year end
1231
CIK
1840439
Session & valuation
Open$1.46
Previous close$1.44
Day high$1.50
Day low$1.39
30-day avg. volume2.3M
Outstanding shares72.5M
Diluted EPS-$1.18
Latest annual period
P/E (trailing)-1.26
P/E (forward)-1.46
Price / book8.23
Beta-0.24
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PLYXPolaryx Therapeutics Inc. Common Stock | $99.4M | $0.00 | — | -$0.20 | 0.00% | Buy |
| PMNProMIS Neurosciences Inc. Common Shares (ON) | $102M | $0.00 | — | -$22.61 | -10.59% | Buy |
| NTHINeOnc Technologies Holdings Inc. Common Stock | $97.4M | $40K | -155404.38% | -$3.20 | +4.04% | Buy |
| BGMBGM Group Ltd. Class A Ordinary Shares | $95.7M | $37.9M | -52.59% | -$0.18 | -2.35% | Unrated |
| MISTMilestone Pharmaceuticals Inc. Common Shares | $95.4M | $1.5M | -4.08% | -$0.75 | -11.83% | Buy |